Skip to main content
SpringerLink
Log in

Palliation of Metastatic Bone Pain with Radiolabeled Phosphonates

  • Chapter
  • First Online:
Clinical Nuclear Medicine

  • 1351 Accesses

Abstract

This chapter reviews the role of various radiolabeled phosphonates in the palliation of bone pain from osteoblastic metastatic and primary bone disease. Various radiophosphonates are available for this purpose. These include Samarium-153 ethylenediaminetetramethylenephosphonate (Samarium-153 EDTMP), Rhenium-188 hydroxyethylidenediphosphonate (Rhenium-188 HEDP), and Lutetium-177 ethylenediaminetetramethylene phosphonic acid (Lutetium-177 EDTMP). They generally have comparatively short physical half-lives and high dose rates and can be administered as either monotherapy or fractionated therapy with low toxicity. They also can be imaged to both assess efficacy and conduct dosimetry studies. One agent that has been studied extensively and approved for bone palliation in a variety of cancers, including prostrate, breast, lung, and other primary cancers, is Samarium-153 EDTMP. It has been shown to be effective with single-dose treatment in 65–85% of patients, with pain relief seen within 4–6 weeks of treatment. Initial positive responses have been sustainable over longer periods, with significant reduction in opioid and other analgesic needs, overall improvement in quality of life, and survival benefits with minimal short- and long-term adverse events. Additionally, more recent studies have demonstrated that it can be safe to combine Samarium-153 EDTMP with chemotherapy, external beam radiation therapy, and nonradioactive bisphosphonates, to palliate metastatic bone pain and provide an antitumor strategy especially for metastatic castration-resistant prostate cancer. More recently, studies have shown that Rhenium-188 HEDP holds promise because it appears to be effective in rapidly relieving pain and improving overall survival in patients with prostate cancer when given as repeated therapy, it is readily available from a generator, and it is cost-effective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996.

    Google Scholar 

  2. Cecchini M, Wetterwald A, Pluijm G, Thalmann G. Molecular and biological mechanisms of bone metastasis. EAU Upd Ser. 2005;3:214–26.

    Google Scholar 

  3. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.

    CAS  PubMed  Google Scholar 

  4. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone metastases: an overview. Oncol Rev. 2017;11(1):321.

    PubMed  PubMed Central  Google Scholar 

  5. Alavi M, Omidvari S, Mehdizadeh A, Jalilian AR, Bahrami-Samani A. Metastatic bone pain palliation using (177) Lu-ethylenediaminetetramethylene phosphonic acid. World J Nucl Med. 2015;14(2):109–15.

    PubMed  PubMed Central  Google Scholar 

  6. Blake GM, Wood JF, Wood PJ, Zivanovic MA, Lewington VJ. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med. 1989a;15(1):49–54.

    CAS  PubMed  Google Scholar 

  7. Blake GM, Zivanovic MA, Lewington VJ. Measurements of the strontium plasma clearance rate in patients receiving Sr89 radionuclide therapy. Eur J Nucl Med. 1989b;15(12):780–3.

    CAS  PubMed  Google Scholar 

  8. Guerra Liberal FDC, Tavares AAS, Tavares JMRS. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Radiat Isot. 2016;110:87–99.

    CAS  PubMed  Google Scholar 

  9. Guerra Liberal FD, Tavares AA, Tavares JM. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys. 2014;41(11):114101. https://doi.org/10.1118/1.4897240.

    Article  CAS  PubMed  Google Scholar 

  10. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med. 1999;40(2):256–61.

    CAS  PubMed  Google Scholar 

  11. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, Investigators ALSYMPACA. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.

    CAS  PubMed  Google Scholar 

  12. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88(12 Suppl):2934–9.

    CAS  PubMed  Google Scholar 

  13. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–81.

    CAS  PubMed  Google Scholar 

  14. Srivastava SC, Aktins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G, Mausner LF, Swailem F, D’Alessandro T, Cabahug CJ, Lau Y, Park T, Madajewicz S. Treatment of metastatic bone pain with tin-177m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res. 1998;4(1):61–8.

    CAS  PubMed  Google Scholar 

  15. Srivastava SC, Meinken GE, Richards P, et al. The development and in-vivo behavior of tin containing radiopharmaceuticals I. Chemistry, preparation and biodistribution in small animals. Int J Nucl Med Biol. 1985;12:167–74.

    CAS  PubMed  Google Scholar 

  16. Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP, Basu S. Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases. J Nucl Med. 2015;56(10):1513–9.

    CAS  PubMed  Google Scholar 

  17. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12(9):447–54.

    CAS  PubMed  Google Scholar 

  18. Kaplan E, Fels IG, Kotlowski BR. Therapy of carcinoma of the prostate metastatic to bone with P-32 labeled condensed phosphate. J Nucl Med. 1960;1:1–13.

    Google Scholar 

  19. Karasawa K. Cancer therapy using unsealed radioisotopes-the present and future. Gan To Kagaku Ryoho. 2014;41(13):2555–8.

    PubMed  Google Scholar 

  20. Kutzner J, Dähnert W, Schreyer T, Grimm W, Bord KH, Becker M. Yttrium-90 zur Strahlentherapie von Knochenmetastasen. Nucl Med. 1981;20:229–35.

    CAS  Google Scholar 

  21. Bertolaso P, Leroy L, Gross-Goupil M, Aupee O, Ravaud A, Roubaud G, Cazeau AL, Le Moulec S. Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: state of arts. Bull Cancer. 2017;104(9):762–70.

    PubMed  Google Scholar 

  22. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.

    CAS  PubMed  Google Scholar 

  23. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O’Sullivan JM, Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–16.

    CAS  PubMed  Google Scholar 

  24. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–46.

    CAS  PubMed  Google Scholar 

  25. Ando A, Ando I, Tonami N, Kinuya S, Kazuma K, Kataiwa A, Nakagawa M, Fujita N. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Commun. 1998;19(6):587–91.

    CAS  PubMed  Google Scholar 

  26. De Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med. 1992;33(5):646–51.

    PubMed  Google Scholar 

  27. Ketring AR. 153 Sm-EDTMP and 186 Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B. 1987;14(3):223–32.

    CAS  PubMed  Google Scholar 

  28. Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Risse J, Krebs D, Biersack HJ. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med. 1999;24(9):643–8.

    CAS  PubMed  Google Scholar 

  29. Palmedo H, Bender H, Schomburg A, Grünwald F, Schöneich G, Zamorra P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ. Pain therapy with rhenium-186 HEDP in multiple bone metastases. Nuklearmedizin. 1996;35(2):63–7. German.

    CAS  PubMed  Google Scholar 

  30. Palmedo H, Grünwald F, Wagner U, Köhler S, Krebs D, Biersack HJ. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP. Clin Nucl Med. 1998;23(8):501–4.

    CAS  PubMed  Google Scholar 

  31. Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, Ezziddin S, Bucerius J, von Mallek D. Palliation and survival after repeated (188) Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52(11):1721–6.

    CAS  PubMed  Google Scholar 

  32. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grünwald F, Knapp FF Jr, Biersack HJ. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000;27(2):123–30.

    CAS  PubMed  Google Scholar 

  33. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21(15):2869–75.

    CAS  PubMed  Google Scholar 

  34. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33(8):1451–8.

    CAS  PubMed  Google Scholar 

  35. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994;35(1):63–9.

    CAS  PubMed  Google Scholar 

  36. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34(7):1031–6.

    CAS  PubMed  Google Scholar 

  37. Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30(11):1814–8.

    CAS  PubMed  Google Scholar 

  38. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34(11):1839–44.

    CAS  PubMed  Google Scholar 

  39. Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol. 1997;43(2):175–9.

    CAS  PubMed  Google Scholar 

  40. Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C, Correa-Hernández L. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res. 2014;45(4):301–8.

    PubMed  Google Scholar 

  41. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010;40(2):89–104.

    PubMed  Google Scholar 

  42. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33(10):1583–91.

    CAS  PubMed  Google Scholar 

  43. Sapienza MT, Ono CR, Guimarães MI, Watanabe T, Costa PA, Buchpiguel CA. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev Hosp Clin Fac Med Sao Paulo. 2004;59(6):321–8.

    PubMed  Google Scholar 

  44. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P, Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.

    PubMed  Google Scholar 

  45. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26(1):2–7.

    CAS  PubMed  Google Scholar 

  46. Velasco Latrás M, Carreras Coderch L, Antoñanzas Villar F, Coya Viña J, Martín Comín J, Martínez Carderón F, Nieto Martín-Bejarano J, Sáenz Cusí A, Serrano Bermúdez G, Echevarría IA. Cost-effectiveness analysis of samarium153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases. Clin Transl Oncol. 2005;7(5):198–204.

    PubMed  Google Scholar 

  47. Macedo A, Araújo A, Melo FC, Nunes G, Cantinho G, Amorin I. Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal. Acta Med Port. 2006;19(5):421–6.

    CAS  PubMed  Google Scholar 

  48. Tripathi M, Singhal T, Chandrasekhar N, Kumar P, Bal C, Jhulka PK, Bandopadhyaya G, Malhotra A. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer. 2006;43(2):86–92.

    CAS  PubMed  Google Scholar 

  49. Dolezal J. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases. Onkologie. 2009;32(1-2):35–9.

    CAS  PubMed  Google Scholar 

  50. Petersen LJ, Lund L, Jønler M, Jakobsen M, Abrahamsen J. Samarium-153 treatment of bone pain in patients with metastatic prostate cancer. Dan Med Bull. 2010;57(6):A4154.

    PubMed  Google Scholar 

  51. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27(9):1084–6.

    CAS  PubMed  Google Scholar 

  52. Menda Y, Bushnell DL, Williams RD, et al. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med. 2000;25:698–700.

    CAS  PubMed  Google Scholar 

  53. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109:637–43.

    CAS  PubMed  Google Scholar 

  54. Higano CS, Quick DP, Bushnell D, Sartor O. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. Clin Genitourin Cancer. 2008;6(1):40–5.

    CAS  PubMed  Google Scholar 

  55. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429.

    CAS  PubMed  Google Scholar 

  56. Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, DeWeese T, Eisenberger MA. Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2011;29:670–5.

    CAS  PubMed  Google Scholar 

  57. Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ. Repetitively dosed docetaxel and 153-samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013;119:3186–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Baczyk M, Milecki P, Pisarek M, Gut P, Antczak A, Hrab M. A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases. Neoplasma. 2013;60(3):328–33.

    CAS  PubMed  Google Scholar 

  59. Baczyk M, Baczyk E, Sowiński J. Preliminary results of combined application of radioisotopes and biphosphonates in the management of pain associated with osteoblastic-osteolytic bone metastases of breast cancer. Ortop Traumatol Rehabil. 2003;5(2):234–7.

    PubMed  Google Scholar 

  60. Rasulova N, Lyubshin V, Arybzhanov D, Sagdullaev S, Krylov V, Khodjibekov M. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease. World J Nucl Med. 2013;12(1):14–8.

    PubMed  PubMed Central  Google Scholar 

  61. Lam MG, de Klerk JM, Zonnenberg BA. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined. J Palliat Med. 2009;12(7):649–51.

    PubMed  Google Scholar 

  62. Ahmadzadehfar H. Targeted therapy for metastatic prostate cancer with radionuclides. In: Mohan R, editor. Prostate cancer. Rijeka: IntechOpen; 2016. https://doi.org/10.5772/64016. Available from https://www.intechopen.com/books/prostate-cancer-leading-edge-diagnostic-procedures-and-treatments/targeted-therapy-for-metastatic-prostate-cancer-with-radionuclides.

    Chapter  Google Scholar 

  63. Chhabra A, Rathore Y, Bhusari P, Vatsa R, Mittal BR, Shukla J. Concentration protocol of rhenium-188 perrhenate eluted from tungsten-188/rhenium-188 generator for the preparation of high-yield rhenium-188-labelled radiopharmaceuticals. Nucl Med Commun. 2018;39:957. https://doi.org/10.1097/MNM.0000000000000893.

    Article  CAS  PubMed  Google Scholar 

  64. Knapp FF Jr, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo H, Biersack HJ. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 1997;17(3B):1783–95.

    CAS  PubMed  Google Scholar 

  65. Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF Jr, Franke WG. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003;44(6):953–60.

    CAS  PubMed  Google Scholar 

  66. Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin. 2016;55(5):188–95.

    PubMed  Google Scholar 

  67. Mazzarri S, Guidoccio F, Mariani G. The emerging potential of 177Lu-EDTMP: an attractive novel option for radio metabolic therapy of skeletal metastases. Clin Transl Imag. 2015;3(2):167–8.

    Google Scholar 

  68. Abbasi IA. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation. Nucl Med Biol. 2011;38(3):417–25.

    CAS  PubMed  Google Scholar 

  69. Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D, Zaknun JJ, Pillai MR, Jánoki GA. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol. 2010;37(2):215–26.

    PubMed  Google Scholar 

  70. Agarwal KK, Singla S, Arora G, Bal C. (177) Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging. 2015;42(1):79–88.

    CAS  PubMed  Google Scholar 

  71. Sharma S, Singh B, Koul A, Mittal BR. Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients’ pain score analysis and personalized dosimetry. Front Med (Lausanne). 2017;4:46. https://doi.org/10.3389/fmed.2017.00046.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, Department of Radiology, Jackson Memorial Hospital, Sylvester Comprehensive Cancer Center Miller School of Medicine, University of Miami, Miami, FL, USA

    Jiaqiong Wang

  2. Nuclear Medicine, Department of Radiology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

    Aldo N. Serafini

Authors
  1. Jiaqiong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aldo N. Serafini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aldo N. Serafini .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Klinikum Westfalen - Knappschaftskrankenhaus Academic teaching hospital of the Ruhr University, Dortmund, Nordrhein-Westfalen, Germany

    Hojjat Ahmadzadehfar

  2. Department of Nuclear Medicine, Beta Klinik Bonn, Bonn, Germany

    Hans-Jürgen Biersack

  3. Division of Nuclear Medicine, Department of Radiology, Montefiore Medical Center, Bronx, NY, USA

    Leonard M. Freeman

  4. Albert Einstein College of Medicine, Bronx, NY, USA

    Lionel S. Zuckier

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wang, J., Serafini, A.N. (2020). Palliation of Metastatic Bone Pain with Radiolabeled Phosphonates. In: Ahmadzadehfar, H., Biersack, HJ., Freeman, L., Zuckier, L. (eds) Clinical Nuclear Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-39457-8_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-39457-8_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-39455-4

  • Online ISBN: 978-3-030-39457-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation